CRISPR Therapeutics
Market Cap
US$2.7b
Last Updated
2019/09/18 01:21 UTC
Data Sources
Company Financials +
Executive Summary
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases.
Snowflake
Fundamentals
Excellent balance sheet with concerning outlook.
Similar Companies
Share Price & News
How has CRISPR Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.8%
NasdaqGM:CRSP
-0.5%
US Biotechs
-0.02%
US Market
1 Year Return
-5.1%
NasdaqGM:CRSP
-11.3%
US Biotechs
1.6%
US Market
CRSP outperformed the Biotechs industry which returned -9.7% over the past year.
CRSP underperformed the Market in United States of America which returned 2.1% over the past year.
Share holder returns
| CRSP | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.8% | -0.5% | -0.02% |
| 30 Day | 1.3% | -2.1% | 2.7% |
| 90 Day | 11.0% | -1.9% | 1.4% |
| 1 Year | -5.1%-5.1% | -10.6%-11.3% | 3.8%1.6% |
| 3 Year | n/a | 4.6%1.1% | 45.2%35.8% |
| 5 Year | n/a | 1.9%-3.0% | 61.8%44.1% |
Price Volatility Vs. Market
How volatile is CRISPR Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares A Year Ago Are Now Down 12%2 months ago | Simply Wall St
Could The CRISPR Therapeutics AG (NASDAQ:CRSP) Ownership Structure Tell Us Something Useful?4 months ago | Simply Wall St
The CRISPR Therapeutics (NASDAQ:CRSP) Share Price Is Down 35% So Some Shareholders Are Getting WorriedValuation
Is CRISPR Therapeutics undervalued based on future cash flows and its price relative to the stock market?
7.16x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for CRISPR Therapeutics to establish if it is available at moderate discount.
Unable to calculate intrinsic value for CRISPR Therapeutics to establish if it is available at substantial discount.
Price Based on Earnings
CRISPR Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
CRISPR Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for CRISPR Therapeutics, we can't assess if its growth is good value.
Price Based on Value of Assets
CRISPR Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
Next Steps
Future Growth
How is CRISPR Therapeutics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?
-6.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
CRISPR Therapeutics's revenue is expected to grow by 7.4% yearly, however this is not considered high growth (20% yearly).
CRISPR Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
CRISPR Therapeutics's revenue growth is expected to exceed the United States of America market average.
Unable to compare CRISPR Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare CRISPR Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if CRISPR Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has CRISPR Therapeutics performed over the past 5 years?
-54.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
CRISPR Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare CRISPR Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare CRISPR Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if CRISPR Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if CRISPR Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if CRISPR Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is CRISPR Therapeutics's financial position?
Financial Position Analysis
CRISPR Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
CRISPR Therapeutics's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
CRISPR Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
Unable to establish if CRISPR Therapeutics's debt level has increased without past 5-year debt data.
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are -6.1709588731626E+16x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
CRISPR Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
CRISPR Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 70.2% each year.
Next Steps
Dividend
What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate CRISPR Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate CRISPR Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as CRISPR Therapeutics has not reported any payouts.
Unable to verify if CRISPR Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as CRISPR Therapeutics has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of CRISPR Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of CRISPR Therapeutics's salary, the management and board of directors tenure and is there insider trading?
2.0yrs
Average management tenure
CEO
Samarth Kulkarni (40yo)
0yrs
Tenure
US$9,727,531
Compensation
Dr. Samarth Kulkarni, Ph.D., has been the Chief Executive Officer of CRISPR Therapeutics AG since December 1, 2017 and served as its President since May 4, 2017 until December 1, 2017 and its Chief Busines ...
CEO Compensation Analysis
Samarth's remuneration is higher than average for companies of similar size in United States of America.
Samarth's compensation has increased whilst company is loss making.
Management Age and Tenure
2.0yrs
Average Tenure
52yo
Average Age
The average tenure for the CRISPR Therapeutics management team is less than 2 years, this suggests a new team.
Board Age and Tenure
1.8yrs
Average Tenure
52.5yo
Average Age
The average tenure for the CRISPR Therapeutics board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Company |
| Shares | 65,934 |
| Max Price | US$33.17 |
| Entity | Company |
| Shares | 40,198 |
| Max Price | US$24.95 |
| Entity | Company |
| Shares | 90,742 |
| Max Price | US$24.97 |
Ownership Breakdown
Management Team
Craig Mello
Scientific Founder & Advisory Board Member
- Tenure: 0yrs
Rodger Novak (52yo)
Founder
- Tenure: 1.8yrs
- Compensation: US$645.57k
Shaun Foy
- Tenure: 0yrs
Chad Cowan
Scientific Founder
- Tenure: 0yrs
Mike Tomsicek (53yo)
Chief Financial Officer
- Tenure: 1.8yrs
- Compensation: US$2.25m
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Matthew Porteus
Scientific Founder & Advisory Board Member
- Tenure: 0yrs
Samarth Kulkarni (40yo)
CEO & Director
- Tenure: 0yrs
- Compensation: US$9.73m
James Kasinger (47yo)
General Counsel & Secretary
- Tenure: 2.3yrs
- Compensation: US$3.16m
Tony Ho (53yo)
Executive Vice President of Research & Development
- Tenure: 2.1yrs
- Compensation: US$4.15m
Board Members
Pablo Cagnoni (56yo)
Independent Director
- Tenure: 3.8yrs
- Compensation: US$648.79k
Craig Mello
Scientific Founder & Advisory Board Member
- Tenure: 0yrs
Rodger Novak (52yo)
Founder
- Tenure: 1.8yrs
- Compensation: US$645.57k
Dan Anderson
Scientific Founder & Advisory Board Member
- Tenure: 0yrs
Simeon George (42yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: US$643.79k
Bill Lundberg (56yo)
Head of Scientific Advisory Board
- Tenure: 1.6yrs
- Compensation: US$2.58m
John Greene (53yo)
Director
- Tenure: 0.3yrs
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Matthew Porteus
Scientific Founder & Advisory Board Member
- Tenure: 0yrs
Samarth Kulkarni (40yo)
CEO & Director
- Tenure: 0yrs
- Compensation: US$9.73m
Company Information
CRISPR Therapeutics AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CRISPR Therapeutics AG
- Ticker: CRSP
- Exchange: NasdaqGM
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.690b
- Shares outstanding: 54.66m
- Website: https://www.crisprtx.com
Number of Employees
Location
- CRISPR Therapeutics AG
- Baarerstrasse 14
- Zug
- Zug
- 6300
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRSP | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | Oct 2016 |
| 1CG | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Oct 2016 |
| 0VRQ | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Oct 2016 |
Biography
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/18 01:21 |
| End of Day Share Price | 2019/09/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.